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fatty acid confers better improvement of
dyslipidemia and endothelium function
Xianbing Song1, Hongsheng Liu2, Xiaotian Wang3, Zhenhua Li3* and Congwu Huang4Abstract
Background: Atorvastatin and poly-unsaturated fatty acid (PUFA) are beneficial for lipid-modification, whether
atorvastatin plus PUFA could confer better improvement on dyslipidemia and endothelium function is unknown.
Methods: Dyslipidemia model of 40 rabbits were produced with atherogenic diet, and thereafter saline,
atorvastatin, PUFA, or atorvastatin plus PUFA were prescribed for 1 week. Ten rabbits given normal diet served as
the sham group. Parameters of interest including lipid profiles, endothelium function (nitric oxide, NO) and
activation (solution vascular-cellular adhesion molecule, (sVCAM) and intracellular adhesion molecule, (sICAM)),
markers of inflammation (C-reactive protein, CRP) and oxidation (malondialdehyde, MDA) were compared
among groups.
Results: There was no significant difference of parameters among groups at the initial. With 1 week of atherogenic
diet administration, serum levels of lipid profiles, sVCAM and sICAM, CRP and MDA were significantly increased,
accompanying with profound NO reduction, as compared to the sham group. After 1 week of medical intervention,
as compared to the control group (saline administration), dyslipidemia and endothelium function were modestly
improved with either atorvastatin or PUFA therapy. Nevertheless, these efficacies were further and significantly
enhanced with combined therapy when compared to the control group (p < 0.005), suggesting that there was
synergistic effects of atorvastatin and PUFA co-therapy in rabbits with dyslipidemia.
Conclusion: Atorvastatin plus PUFA therapy could immediately contribute to better improvement of
lipid-modification and endothelium function in rabbits with dyslipidemia.
Keywords: Dyslipidemia, Endothelium function, Synergistic effectIntroduction
Dyslipidemia, predominantly characterized by eleva-
ted serum levels of low density lipoprotein-cholesterol
(LDL-C) and triglyceride and decreased high density
lipoprotein-cholesterol (HDL-C), is the major cause of
atherosclerosis and atherosclerotic cardiovascular diseases
[1,2]. 3-hydroxy-3-methylglutaryl coenzyme-A reductase
(HMG-CoA reductase) inhibitor, statin, has been broadly
applied to treat dyslipidemia and atherosclerosis [3,4].
Other than statin, in the past decades, some experimental
studies showed that poly-unsaturated fatty acid (PUFA)* Correspondence: lzh186@yeah.net
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unless otherwise stated.were also beneficial for lipid-modification [5,6]. Addition-
ally, data from some epidemiological studies indicated that
increased PUFA consumption could not only result in bet-
ter improvement of dyslipidemia, but also be possible to
retard the progression of atherosclerosis [7-9]. Neverthe-
less, since nearly almost every patient with dyslipidemia is
treated with statin currently, therefore whether the benefit
of PUFA render to lipid-modification is independent of or
is overlapped with statin therapy is deserved to be further
investigated, especially its associated mechanisms. Addi-
tionally, whether statin combined with PUFA could better
improve dyslipidemia and endothelium function in the
early stage is also unclear.
In light of previous findings, we conducted an experi-
mental study to compare the efficacy of statin and PUFAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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over, since endothelium dysfunction and activation is
implicated in the early stage of atherosclerosis under the
setting of dyslipidemia, the effect of PUFA on endothe-
lial function and its associated mechanisms would also
be evaluated herein. We believed that data from our
current study would provide more evidence regarding
the effect and application of PUFA on the primary and
secondary prevention of atherosclerotic cardiovascular
diseases in subjects with dyslipidemia.
Methods
Dyslipidemia animal model production
Totally 50 male New Zealand White rabbits, weighing
1.2-1.5 kilogram and with 6–8 weeks old, were obtained
from Experimental Animal Center of Shantou University,
and the protocol of current study was approved by Ethic
Committee of Shantou University. Briefly, 10 rabbits were
served as the sham group, and another 40 rabbits were
used as dyslipidemia group, which were prescribed with
atherogenic diet containing 0.5% cholesterol for 1 week as
described by previous study [10].
Studied protocol
Rabbits with dyslipidemia were randomly and evenly
assigned into the control group (3 ml of normal saline
administration), atorvastatin group (5 mg/kg body weight/
day of atorvastatin reconstituted in 3 ml normal saline,
oral administration), PUFA group (Eicosapentaenoic acid/
Docosahexaenoic acid, EPA/DHA with 1:1 ratio, 10 ml/
day was added into diet), and combined group (prescribed
the same doses of atorvastatin and PUFA as above), and
the sham group was prescribed with 3 ml normal saline.
The duration of intervention lasted for 1 week.
Laboratory examination
At initial, 1 week of atherogenic diet administration, and
1 week after medical intervention, fasting blood was
sampled for assessing parameters of interest, including
lipid profile (including TG, TC, LDL-C and HDL-C), ni-
tric oxide (NO) production, serum levels of C-reactive
protein (CRP), solution vascular-cellular adhesion mol-
ecule (sVCAM), solution intracellular adhesion molecule
(sICAM) and malondialdehyde (MDA), were evaluated.
All procedures were performed according to the manufac-
ture instruction and three independent experiments were
performed in duplicate.
Statistical analyses
Continuous variable was presented as mean ± SD and
compared by the Student’s t-test when data was nor-
mally distributed, otherwise compared by Wilcoxon rank-
sum test. Statistical analyses were performed by usingSPSS software version 18.0 (SPSS, Inc., Chicago, Illinois).
A value of p <0.05 was considered significant.
Results
Comparison of parameters between the sham and
dyslipidemia groups
Briefly, parameters of interest at the initial and at 1 week
of atherogenic diet treatment were compared among
groups. As presented in Table 1, there was no significant
difference of lipid profile, NO production, serum levels
of CRP, sVCAM, sICAM and MDA between the sham
and dyslipidemia groups. Nevertheless, with 1 week of
atherogenic diet administration, except HDL-C, serum
levels of TG, TC, LDL-C were significantly increased in
the dyslipidemia group as compared to the sham group
(p < 0.05). Additionally, NO production was profoundly
declined in accompany with elevation of CRP, sVCAM,
sICAM and MDA in the dyslipidemia groups (p < 0.05).
Comparison of effects of different interventions
With 1 week’s medical intervention, parameters of inter-
est among groups were evaluated so as to compare the
effects of different interventions. As shown in Table 2, in
comparison to the control group, serum levels of TG,
TC and LDL-C were slightly but not significantly reduced
in the atorvastatin or PUFA therapy groups (p > 0.05). The
modest improvement of NO production, and marginal
reduction of serum levels of CRP, sVCAM, sICAM and
MDA were also observed between the control and the
atorvastatin and PUFA therapy groups (p > 0.05). Never-
theless, in comparison to the control group, the improve-
ments of lipid profiles, endothelium dysfunction and
activation and systemic inflammation and oxidation were
profoundly enhanced by combined therapy (p < 0.05),
strongly suggesting that atorvastatin plus PUFA adminis-
tration had synergistic protective effects in rabbits with
dyslipidemia.
Discussion
With regard to its potent lipid-lowering and pleiotropic
effects, statin has been defined as the cornerstone of
dyslipidemia and atherosclerosis therapy [3,4]. Poly-
unsaturated fatty acid, a significant and essential nutri-
tion, now has also been recommended by some expertise
of cardiology and nutrition for the adjunctive therapy of
dyslipidemia and atherosclerotic cardiovascular diseases
[11-13]. But the mechanisms of PUFA on dyslipidemia-
modification and atherosclerosis-prevention are far less
clear. Moreover, whether statin plus PUFA therapy could
confer more robust efficacy on cardiovascular system
needs further investigation. Data from our current experi-
mental study show that in rabbits with dyslipidemia, as
compared to the control group, 1 week of atorvastatin or
PUFA therapy slightly improve dyslipidemia. Moreover,
Table 1 Parameters comparison between the sham and dyslipidemia groups
Variables Sham (n = 10) Control (n = 10) Atorvastatin (n = 10) PUFA (n = 10) Combined (n = 10)
At initial
TG (mmol/L) 1.08 ± 0.11 1.03 ± 0.12 1.04 ± 0.10 1.06 ± 0.11 1.04 ± 0.12
TC (mmol/L) 3.82 ± 0.21 3.80 ± 0.16 3.81 ± 0.17 3.78 ± 0.16 3.78 ± 0.14
LDL-C (mmol/L) 2.03 ± 0.15 1.98 ± 0.12 2.01 ± 0.12 2.00 ± 0.12 2.01 ± 0.13
HDL-C (mmol/L) 0.92 ± 0.06 0.92 ± 0.05 0.93 ± 0.07 0.91 ± 0.03 0.90 ± 0.07
NO (μmol/L) 12.24 ± 1.23 12.09 ± 1.16 12.13 ± 1.17 12.20 ± 1.09 12.12 ± 1.18
CRP (mg/L) 2.08 ± 0.36 2.11 ± 0.23 2.04 ± 0.29 2.10 ± 0.19 2.11 ± 0.24
sVCAM (μg/mL) 3.52 ± 0.26 3.57 ± 0.33 3.49 ± 0.20 3.50 ± 0.30 3.52 ± 0.35
sICAM (μg/mL) 0.43 ± 0.06 0.41 ± 0.03 0.44 ± 0.05 0.43 ± 0.05 0.42 ± 0.05
MDA (nmol/L) 0.86 ± 0.05 0.89 ± 0.05 0.82 ± 0.04 0.86 ± 0.07 0.85 ± 0.04
1 week of atherogenic diet treatment
TG (mmol/L) 1.10 ± 0.12* 1.23 ± 0.18 1.24 ± 0.13 1.20 ± 0.09 1.22 ± 0.06
TC (mmol/L) 3.85 ± 0.20* 4.35 ± 0.13 4.40 ± 0.17 4.41 ± 0.12 4.38 ± 0.11
LDL-C (mmol/L) 2.06 ± 0.12* 2.35 ± 0.26 2.32 ± 0.32 2.30 ± 0.26 2.30 ± 0.21
HDL-C (mmol/L) 0.93 ± 0.06 0.90 ± 0.06 0.90 ± 0.07 0.91 ± 0.03 0.92 ± 0.05
NO (μmol/L) 12.18 ± 1.09* 9.26 ± 1.02 9.23 ± 1.06 9.25 ± 1.02 9.20 ± 1.07
CRP (mg/L) 2.07 ± 0.32* 4.63 ± 0.43 4.61 ± 0.34 4.58 ± 0.30 4.60 ± 0.26
sVCAM (μg/mL) 3.50 ± 0.25* 4.95 ± 0.42 4.92 ± 0.36 4.92 ± 0.18 4.93 ± 0.27
sICAM (μg/mL) 0.44 ± 0.05* 0.58 ± 0.07 0.56 ± 0.06 0.63 ± 0.08 0.65 ± 0.06
MDA (nmol/L) 0.88 ± 0.04* 1.09 ± 0.06 1.05 ± 0.04 1.07 ± 0.04 1.07 ± 0.06
Denote: *p < 0.05 versus other groups.
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well as inflammation and oxidative stress are also mo-
destly ameliorated. When atorvastatin combined with
PUFA administration, however, the efficacies are further
enhanced as compared to either atorvastatin or PUFA
therapy alone, strongly suggesting synergistic effects
exit between statin and PUFA in treatment of early
stage of dyslipidemia.
Basically, disorders of lipid metabolism not only
results from over-consumption of cholesterol and trigly-
ceride, but also associated with the alteration of the
profile of individual lipid molecule [14,15]. Via inhibitingTable 2 Comparison of effects of different intervention
Variables Sham (n = 10) Control (n = 10) A
TG (mmol/L) 1.07 ± 0.09 1.26 ± 0.14
TC (mmol/L) 3.84 ± 0.15 4.32 ± 0.11
LDL-C (mmol/L) 2.02 ± 0.11 2.33 ± 0.20
HDL-C (mmol/L) 0.92 ± 0.03 0.91 ± 0.03
NO (μmol/L) 12.18 ± 1.16 9.02 ± 1.00
CRP (mg/L) 2.10 ± 0.39 4.68 ± 0.37
sVCAM (μg/mL) 3.48 ± 0.22 4.98 ± 0.24
sICAM (μg/mL) 0.40 ± 0.04 0.58 ± 0.05
MDA (nmol/L) 0.82 ± 0.06 1.10 ± 0.08
Denote: #p < 0.05 versus control group.HMG-CoA reductase, statin blocks the process of chol-
esterol synthesis. Additionally, by means of reducing the
generation of farnesylpyrophosphate (FPP) and geranyl-
geranylpyrophosphate (GGPP), statin exerts its pleio-
tropic effects such as improving endothelium function,
ameliorating inflammation and oxidation, promoting
angiogenesis and anti-apoptosis [16,17]. Accordingly,
the early stage of endothelium dysfunction and activa-
tion majorly manifested as decreased NO production
and increased sICAM and sVCAM generation [18,19].
Data from our current study was consistent with previ-
ous findings [19,20]. As compared to the control group,torvastatin (n = 10) PUFA (n = 10) Combined (n = 10)
1.18 ± 0.12 1.20 ± 0.17 1.11 ± 0.08#
4.16 ± 0.16 4.18 ± 0.13 4.06 ± 0.06#
2.17 ± 0.25 2.19 ± 0.17 2.10 ± 0.12#
0.92 ± 0.04 0.95 ± 0.06 1.01 ± 0.03#
10.27 ± 1.14 10.14 ± 1.08 10.88 ± 1.04#
3.67 ± 0.42 3.72 ± 0.33 3.28 ± 0.30#
4.46 ± 0.53 4.49 ± 0.27 4.17 ± 0.38#
0.53 ± 0.03 0.53 ± 0.04 0.49 ± 0.04#
1.02 ± 0.03 1.03 ± 0.03 0.96 ± 0.05#
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lium function were slightly improved in the atorvastatin
group, although without significant difference. To our best
knowledge, it might be due to either short-term or low-
dose of atorvastatin administration. Previously [21], our
study showed that in rats with dyslipidemia, 10 mg/kg
body weight/day of atorvastatin administration for 2 weeks
significantly improved dyslipidemia as compared to the
control group. In addition, serum levels of CRP and MDA
were also modestly reduced. Of note, since our current
study was to evaluate whether PUFA could exert protec-
tive effect on endothelium function and whether PUFA
could improve dyslipidemia immediately, therefore we
pre-defined 1 week of intervention as the time-point for
outcome assessment. In light of previous reports and our
published study, we believed that it was doubtless that
atorvastatin could profoundly correct the disorder of lipid
metabolism and endothelium dysfunction with time.
Notably, eicosapentaenoic acid (EPA) and docosa-
hexenoic acid (DHA) are the two key components of
PUFA and there were studies showing that EPA and
DHA were beneficial for lipid-modification, hypertension-
management and glycemic-control [22,23]. Moreover,
increased PUFA consumption may retard the progres-
sion of atherosclerosis and even reduce the incidence of
cardiovascular events [22-25]. Consistent with previous
studies [26,27], data from our study also revealed that
10 ml/day of EPA/DHA with 1:1 ratio marginally im-
proved dyslipidemia and endothelium function, although
without statistical significance. We speculated that it
might be also related with the short-term use of PUFA.
In the future, it is imperative to address whether pro-
longed PUFA administration could result in better im-
provement of dyslipidemia and endothelium function.
Importantly, contrast to the slight improvement with
either atorvastatin or PUFA treatment, atorvastatin com-
bined with PUFA profoundly improved both dyslipidemia
and endothelium function, even with 1 week’s adminis-
tration, suggesting that there might be robust synergistic
effects of atorvastatin and PUFA on treating early stage of
dyslipidemia and endothelium dysfunction. To our best
knowledge, some mechanisms might be attributed to this
finding. In the first place, both statin and PUFA are
capable to modify dyslipidemia as reflected in previous
reports and our current study [21,28]. However, when
used alone with a short duration, these benefits of sta-
tin or PUFA therapy might not possible turn into pro-
minence. Therefore, co-therapy with statin and PUFA
might enhance the modest efficacy of lipid-modification
and endothelium-improvement immediately. Secondly,
as mentioned before that statin could inhibit cholesterol
biosynthesis while PUFA could improve the disorder of
plasma lipid composition. And data from our study also
revealed that with combined therapy, not only TG, TCand LDL-C were reduced but also HDL-C was increased
as compared to the control group. As is well known that
increased HDL-C level is beneficial for retarding athero-
sclerosis progression [29]. Therefore, we considered that
statin combined with PUFA therapy might through dif-
ferent and complement mechanisms to result in better
improvement of dyslipidemia and endothelium dysfunc-
tion. Last but not the least, both statin and PUFA have
benefits beyond lipid-modification as aforementioned
above, therefore when used in combination, these pleio-
tropic protective effects might synergy and contribute
to better improvement of lipid disorder and endothe-
lium dysfunction.
Conclusion
In conclusion, atorvastatin plus PUFA therapy could
immediately contribute to better improvement of lipid
disorder and endothelium dysfunction in rabbits with
dyslipidemia, and future study is warranted to investi-
gate whether atorvastatin combined with PUFA could
robustly retard established atherosclerotic plaques.
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